TRI
Click for more information
10.7% 2.5¢ trivarx ltd

FDA Approval - before 29 July, page-274

  1. john12
    664 Posts.
    lightbulb Created with Sketch. 42
    clock Created with Sketch.
    28/07/20
    21:39
    Post #: 46136059
    I really hope so. Did you see how long it took for RAP to get rejected by any chanceAnd without hearing anything?
    Have you ever thought that the momentum in share price might not be related to a potential FDA outcome for “STAGER” but related to a potential client acquisition for their non regulated product of ilumen which is the companies main objective at this stage?
    MEB Price at posting: 1.3¢ Sentiment: Buy Disclosure: Held
    Likes Created with Sketch. 5  Upvote
    lightbulb Created with Sketch.  Great analysis
    Stroke 3 Created with Sketch. Comments Created with Sketch. Reply

  2. Top Stories

 

Featured News

AL8 "What is the focus of AL8 and how is management going to attract shareholders to the registry?"
right-arrow Created with Sketch.
NEWS Chris Judd's Talk Ya Book: Tracking Life360 on a journey to the stars
right-arrow Created with Sketch.
NEWS Week 24 Wrap: US contagion sentiment not so contagious; iron ore remains pressured
right-arrow Created with Sketch.
TLX Telix dips as pharma giant abandons US IPO for NASDAQ listing – despite record run
right-arrow Created with Sketch.
CC9 Chariot Corporation marches forward with discovery-level drill program in Wyoming, USA
right-arrow Created with Sketch.
NEWS MiningNews Select Conference: Inflation and global shifts pose funding challenges for Aus miners
right-arrow Created with Sketch.
watchlist Created with Sketch. Add TRI (ASX) to my watchlist
(20min delay)
Last
2.5¢ 		Change
-0.003(10.7%) 		Mkt cap ! $10.24M
Open High Low Value Volume
2.6¢ 2.7¢ 2.5¢ $12.36K 476.1K

Buyers (Bids)

No. Vol. Price($)
1 10000 2.6¢
 

Sellers (Offers)

Price($) Vol. No.
2.7¢ 190000 1
View Market Depth
Last trade - 15.35pm 19/06/2024 (20 minute delay) ?
TRI (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.